Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.57 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | CASP1 | P29466 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | CASP7 | P55210 | 1/20 | 0.44 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.44 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.44 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | ATM | Q13315 | 1/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.40 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.40 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14320372 | 0.90 | MAOA (0.50) | MAPTSMN1; SMN2ALDH1A1MEN1HTT | |
| SCHEMBL14320317 | 0.81 | MAOA (0.53) | MAPTSMN1; SMN2ALDH1A1ALOX15MEN1 | |
| SCHEMBL2222230 | 0.78 | MGLL (0.50) | ALDH1A1MEN1KMT2ASLC6A2SLC6A4 | |
| SCHEMBL76912 | 0.78 | SMN1; SMN2 (0.52) | SMN1; SMN2ALDH1A1ALOX15KDM4ECASP7 | |
| SCHEMBL6535778 | 0.77 | HSP90AA1 (0.52) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL31333639 | 0.77 | MGLL (0.52) | SMN1; SMN2ALDH1A1MEN1KMT2AATM | |
| SCHEMBL28647818 | 0.77 | MGLL (0.52) | SMN1; SMN2ALDH1A1MEN1KMT2AATM | |
| SCHEMBL18050030 | 0.77 | FGFR1 (0.47) | SMN1; SMN2ALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL13672252 | 0.77 | FAAH (0.52) | MAPTALDH1A1MEN1KMT2AKEAP1 | |
| SCHEMBL143175 | 0.77 | ALDH1A1 (0.54) | MAPTSMN1; SMN2ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 514 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2022-09-01 | — | — | US | claimed |
| EP-2459227-B1 | Prodrugs containing an aromatic amine connected by an amide bond to a carrier | ASCENDIS PHARMA AS (DK) | 2021-03-17 | — | — | EP | claimed |
| EP-3651759-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | Syneurx International (Taiwan) Corp. (TW) | 2020-05-20 | — | — | EP | claimed |
| US-10226442-B2 | Lithium salts of N-substituted glycine compounds and uses thereof | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2019-03-12 | — | — | US | claimed |
| WO-2019014207-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2019-01-17 | — | — | WO | claimed |
| US-20190008813-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SYNEURX INTERNATIONAL (TAIWAN) CORP. (TW) | 2019-01-10 | — | — | US | claimed |
| US-9770514-B2 | Tamper-resistant pharmaceutical dosage forms | ExxPharma Therapeutics LLC (US) | 2017-09-26 | — | — | US | claimed |
| US-9173953-B2 | Prodrugs containing an aromatic amine connected by an amido bond to a linker | ASCENDIS PHARMA AS (DK) | 2015-11-03 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| US-20150064250-A1 | Tamper-Resistant Pharmaceutical Dosage Forms | ExxPharma Therapeutics LLC (US) | 2015-03-05 | — | — | US | claimed |
| WO-2008036798-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-03-27 | — | — | WO | claimed |
| EP-1902742-A1 | Methods and systems of delivering medication via inhalation | Next Safety, Inc. (US) | 2008-03-26 | — | — | EP | claimed |
| US-20080066739-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| CN-100355457-C | Dispersible pharmaceutical compositions | PHARMACIA & UPJOHN CO LLC (US) | 2007-12-19 | — | — | CN | claimed |
| WO-2007061529-A1 | LYOPHILIZATION PROCESS AND PRODUCTS OBTAINED THEREBY | SCIDOSE LLC. (US) | 2007-05-31 | — | — | WO | claimed |
| US-20070116729-A1 | Lyophilization process and products obtained thereby | SCIDOSE LLC | 2007-05-24 | — | — | US | claimed |
| CN-1294519-A | Pharmaceutical composition containing a compound having an activity of promoting the absorption of an active ingredient | INPHARMA SA (CH) | 2001-05-09 | — | — | CN | claimed |
| EP-1073470-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2001-02-07 | — | — | EP | claimed |
| WO-2000048636-A1 | PHARMACEUTICAL COMPOSITIONS CONTAINING COMPOUNDS WITH ACTIVITY FOR THE ENHANCEMENT OF ABSORPTION OF ACTIVE INGREDIENTS | INPHARMA S.A. (CH) | 2000-08-24 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220273600-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SLC1A2, SLC6A5, SLC1A1 | MAPT 2140/4885SMN1; SMN2 3761/4885CASP1 4629/4885 |
| US-10226442-B2 | Lithium salts of N-substituted glycine compounds and uses thereof | SLC1A2, SLC6A5, SLC1A1 | MAPT 2140/4885SMN1; SMN2 3761/4885CASP1 4629/4885 |
| US-20190008813-A1 | LITHIUM SALTS OF N-SUBSTITUTED GLYCINE COMPOUNDS AND USES THEREOF | SLC1A2, SLC6A5, SLC1A1 | MAPT 2140/4885SMN1; SMN2 3761/4885CASP1 4629/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.